Pfizer Yönetim

Yönetim kriter kontrolleri 3/4

Pfizer CEO'su Albert Bourla, Jan2019 tarihinde atandı, in görev süresi 5.83 yıldır. in toplam yıllık tazminatı $ 21.56M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.3% maaş ve 91.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.006% ine doğrudan sahiptir ve bu hisseler $ 8.30M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 7.8 yıldır.

Anahtar bilgiler

Albert Bourla

İcra Kurulu Başkanı

US$21.6m

Toplam tazminat

CEO maaş yüzdesi	8.3%
CEO görev süresi	5.8yrs
CEO sahipliği	0.006%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 01

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

Oct 29

Pfizer: Activists Clouding A Promising Picture

Oct 21

Pfizer: A Strong Product Pipeline Could Lead To Significant Upside

Oct 08

Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'

Oct 01

There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Sep 23

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Sep 23

Why Pfizer Investors Should Closely Monitor VAX-31

Sep 05

Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds

Aug 30

CEO Tazminat Analizi

Albert Bourla'un ücretlendirmesi Pfizer'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 29 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$288m
Dec 31 2023	US$22m	US$2m	US$2b
Oct 01 2023	n/a	n/a	US$10b
Jul 02 2023	n/a	n/a	US$21b
Apr 02 2023	n/a	n/a	US$29b
Dec 31 2022	US$33m	US$2m	US$31b
Oct 02 2022	n/a	n/a	US$30b
Jul 03 2022	n/a	n/a	US$29b
Apr 03 2022	n/a	n/a	US$25b
Dec 31 2021	US$24m	US$2m	US$22b
Oct 03 2021	n/a	n/a	US$19b
Jul 04 2021	n/a	n/a	US$12b
Apr 04 2021	n/a	n/a	US$9b
Dec 31 2020	US$21m	US$2m	US$7b
Sep 27 2020	n/a	n/a	US$212m
Jun 28 2020	n/a	n/a	US$7b
Mar 29 2020	n/a	n/a	US$9b
Dec 31 2019	US$18m	US$2m	US$11b
Sep 29 2019	n/a	n/a	US$16b
Jun 30 2019	n/a	n/a	US$13b
Mar 31 2019	n/a	n/a	US$11b
Dec 31 2018	US$10m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$24b
Jul 01 2018	n/a	n/a	US$23b
Apr 01 2018	n/a	n/a	US$22b
Dec 31 2017	US$9m	US$1m	US$21b

Tazminat ve Piyasa: Albert 'nin toplam tazminatı ($USD 21.56M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 12.73M ).

Tazminat ve Kazançlar: Albert 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Albert Bourla (62 yo)

5.8yrs

Görev süresi

US$21,562,064

Tazminat

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and serves as its Chairman and director of the Board since January 2020 and had been its Executive D...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Albert Bourla	Chairman of the Board & CEO	5.8yrs	US$21.56m	0.0059% $ 8.3m
David Denton	Chief Financial Officer & Executive VP	2.5yrs	US$5.28m	0.00067% $ 946.9k
Mikael Dolsten	Chief Scientific Officer and President of Research & Development	5.8yrs	US$8.86m	0.0057% $ 8.1m
Douglas Lankler	Executive VP & General Counsel	10.9yrs	US$5.48m	0.0026% $ 3.7m
Jennifer Damico	Senior VP	4.7yrs	Veri yok	0.00015% $ 212.0k
Lidia Fonseca	Executive VP and Chief Digital & Technology Officer	5.8yrs	Veri yok	0.00063% $ 890.4k
Francesca DeMartino	Chief Investor Relations Officer	no data	Veri yok	Veri yok
Rady Johnson	Executive VP and Chief Compliance	10.9yrs	Veri yok	0.0018% $ 2.6m
Andreas Panayiotou	Global Chief Marketing Officer	2.2yrs	Veri yok	Veri yok
Payal Becher	Chief People Experience Officer & Executive VP	4.4yrs	Veri yok	0.00063% $ 890.4k
Sally Susman	Executive VP & Chief Corporate Affairs Officer	16.8yrs	Veri yok	0.0029% $ 4.1m
Annette Doherty	Head of Worldwide Pharmaceutical Sciences	19.5yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: PFE 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Albert Bourla	Chairman of the Board & CEO	4.8yrs	US$21.56m	0.0059% $ 8.3m
Shantanu Narayen	Lead Independent Director	11.2yrs	US$430.00k	Veri yok
Ronald Blaylock	Independent Director	7.8yrs	US$380.00k	0.00023% $ 325.1k
Suzanne Nora Johnson	Independent Director	17.2yrs	US$410.00k	0.00018% $ 254.4k
James Smith	Independent Director	10.4yrs	US$390.00k	0.000060% $ 84.8k
Charles Hagel	Member of Emerging Markets Advisory Board	no data	Veri yok	Veri yok
Susan Hockfield	Independent Director	4.7yrs	US$363.00k	Veri yok
Daniel Littman	Independent Director	6.7yrs	US$391.40k	Veri yok
James Robert Quincey	Independent Director	4.8yrs	US$380.00k	Veri yok
Scott Gottlieb	Independent Director	5.4yrs	US$417.20k	0.00018% $ 254.4k
Joseph Echevarria	Independent Director	9.4yrs	US$390.00k	Veri yok
Helen Hobbs	Independent Director	12.9yrs	US$410.00k	Veri yok

7.8yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PFE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Pfizer Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pfizer Inc. Announces Executive Changes

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Recent updates

Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks

Pfizer Inc. Announces Executive Changes

Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer

Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Pfizer Reportedly Explore Sale of Hospital Drugs Unit

Pfizer: Discounted For A Reason - But Dividend Story Remains Rich

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Upcoming dividend of US$0.42 per share

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer: Activists Clouding A Promising Picture

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

Second quarter dividend of US$0.42 announced

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Pfizer: A Strong Product Pipeline Could Lead To Significant Upside

Starboard Value Wants Pfizer to Make Changes to Turn its Performance Around

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'

There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. to Report Q3, 2024 Results on Oct 29, 2024

Pfizer Announces its BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Why Pfizer Investors Should Closely Monitor VAX-31

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş